These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23021209)

  • 1. Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study.
    Miranda Ede P; Abe DK; Nesrallah AJ; dos Reis ST; Crippa A; Srougi M; Dall'Oglio MF
    World J Surg Oncol; 2012 Sep; 10():203. PubMed ID: 23021209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 3. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
    Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
    J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
    Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
    Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Machine Learning Model to Predict the Histology of Retroperitoneal Lymph Node Dissection Specimens.
    Nitta S; Kojima T; Gido M; Nakagawa S; Kakeya H; Kandori S; Kawahara T; Mathis BJ; Kawai K; Negoro H; Nishiyama H
    Anticancer Res; 2024 May; 44(5):2151-2157. PubMed ID: 38677742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors.
    Calaway AC; Kern SQ; Crook D; Tong Y; Masterson TA; Adra N; Einhorn LH; Foster RS; Cary C
    J Urol; 2021 Dec; 206(6):1430-1437. PubMed ID: 34288715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer.
    Beck SD; Foster RS; Bihrle R; Ulbright T; Koch MO; Wahle GR; Einhorn LH; Donohue JP
    J Urol; 2002 Oct; 168(4 Pt 1):1402-4. PubMed ID: 12352402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections.
    Spratt DE; Suresh K; Osawa T; Schipper M; Jackson WC; Abugharib A; Lebastchi A; Smith D; Montgomery JS; Palapattu GS; Priya Kunju L; Wu A; Lew M; Tomlins SA; Chinnaiyan AM; Weizer AZ; Hafez KS; Kaffenberger SD; Udager A; Mehra R
    Med Oncol; 2018 Jan; 35(3):21. PubMed ID: 29387987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
    Aprikian AG; Herr HW; Bajorin DF; Bosl GJ
    Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.
    Nakamura T; Oishi M; Ueda T; Fujihara A; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
    Int J Urol; 2015 Jul; 22(7):663-8. PubMed ID: 25847721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
    Williams SB; Kacker R; Steele GS; Richie JP
    Urol Oncol; 2012; 30(1):60-3. PubMed ID: 20189842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
    Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis.
    Nitta S; Kawai K; Kimura T; Kandori S; Kawahara T; Kojima T; Nishiyama H
    Int J Urol; 2021 Aug; 28(8):840-847. PubMed ID: 34085325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testicular tumors: residual retroperitoneal mass surgery after chemotherapy;Is it possible to predict their histology?
    Medina-Polo J; Martínez-Silva V; Domínguez-Esteban M; de la Rosa-Kehrmann F; Villacampa-Aubá F; Castellano-Gauna D; Díaz-González R
    Arch Esp Urol; 2011 Sep; 64(7):611-9. PubMed ID: 21965259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood testis barrier revisited-Analysis of post-chemotherapy germ cell tumor orchidectomy and retroperitoneal lymph node dissection specimens.
    Gupta A; Noronha J; Bakshi G; Menon S; Pal M; Joshi A; Prabash K; Noronha V; Murthy V; Krishnattry R; Patil A; Prakash GJ
    J Surg Oncol; 2021 Mar; 123(4):1157-1163. PubMed ID: 33428791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
    Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
    J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.
    Herr HW; Toner GC; Geller NL; Bosl GJ
    Eur Urol; 1991; 19(1):1-5. PubMed ID: 1848821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.
    Speir RW; Calaway AC; Einhorn LH; Foster RS; Cary C
    Urol Oncol; 2020 Aug; 38(8):687.e19-687.e23. PubMed ID: 32448503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.